Related Experiment Videos
Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha
Alejandro Sánchez1, María Tobío, Libia González
1Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Summary
New biodegradable microspheres effectively deliver interferon-alpha (IFN-alpha), improving therapeutic potential. PLGA/poloxamer blend microspheres show sustained release of active IFN-alpha for up to 96 days, enhancing treatment options.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Protein Therapeutics
Background:
- Interferon-alpha (IFN-alpha) administration requires improved delivery strategies to enhance efficacy and reduce side effects.
- Poly(lactic-glycolic acid) (PLGA) microspheres are a promising approach, but protein stability upon release is a key concern.
Purpose of the Study:
- To develop and evaluate novel biodegradable micro- and nanoparticles for improved IFN-alpha delivery.
- To enhance the stability and therapeutic effects of IFN-alpha using poloxamer 188 as a stabilizing agent.
Main Methods:
- Encapsulation of IFN-alpha into PLGA/poloxamer blend microspheres via oil-in-oil solvent extraction.
- Preparation of PLGA micro- and nanospheres containing poloxamer using water-in-oil-in-water solvent evaporation.
- Characterization of particle size, IFN-alpha release kinetics (ELISA), and bioactivity (cytostasis bioassay).
Main Results:
- Efficient encapsulation of IFN-alpha achieved with particle sizes ranging from 280 nm to 40 µm.
- Release profiles showed an initial burst followed by sustained release for up to 1 month.
- PLGA/poloxamer blend microspheres demonstrated significant amounts of active IFN-alpha release for up to 96 days, confirmed by bioactivity assays.
Conclusions:
- Novel PLGA/poloxamer micro- and nanosphere formulations offer a viable strategy for stabilizing and delivering IFN-alpha.
- These advanced delivery systems have the potential to significantly improve current IFN-alpha-based therapies by ensuring sustained release of bioactive protein.